Comparing PFO Closure and Medical Treatment for Stroke Prevention
Author Information
Author(s): Khattab Ahmed A, Windecker Stephan, Jüni Peter, Hildick-Smith David, Dudek Dariusz, Andersen Henning R, Ibrahim Reda, Schuler Gerhard, Walton Antony S, Wahl Andreas, Mattle Heinrich P, Meier Bernhard
Primary Institution: Bern University Hospital, Bern, Switzerland
Hypothesis
Is percutaneous device closure of PFO with the Amplatzer PFO Occluder equally effective as medical treatment in preventing recurrent stroke and/or TIA in patients with paradoxical embolism?
Conclusion
The study aims to determine if percutaneous closure of PFO is more effective than medical treatment in preventing recurrent strokes.
Supporting Evidence
- Patients with PFO and ASA are considered high-risk for recurrent events.
- Percutaneous closure of PFO has been shown to be feasible and safe.
- Medical treatment options include antithrombotic therapy with warfarin or antiplatelet agents.
Takeaway
Doctors are trying to find out if closing a hole in the heart helps prevent strokes better than just taking medicine.
Methodology
This is a multicenter, randomized clinical trial comparing percutaneous PFO closure with best medical treatment in patients with PFO and paradoxical embolism.
Potential Biases
Potential biases may arise from the non-randomized nature of treatment assignment in the medical treatment group.
Limitations
The study may not have enough power to draw firm conclusions about the efficacy of different antithrombotic regimens.
Participant Demographics
Patients aged <60 years with a history of cryptogenic stroke or TIA.
Statistical Information
P-Value
0.0492
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website